dotLumen

The .lumen glasses are an innovative assistive technology designed to enhance the mobility and independence of visually impaired individuals. Developed by the Romanian startup .lumen, these glasses combine advanced AI, robotics, and autonomous driving technologies to provide users with enhanced spatial awareness and navigation capabilities.

Key features:
- Pedestrian Autonomous Driving AI: Computes 100 times per second to determine safe walking paths for the user, offering guidance and mobility surpassing that of a guide dog.
- Haptic Feedback for Navigation: Conveys directional information and obstacle alerts through precise vibrations against the forehead, enhancing spatial awareness without relying on visual cues.
- Compatibility and Comfort: Extensively tested to ensure compatibility with 80% of adult head sizes and shapes, providing a comfortable fit for daily use.
- Durability: Designed and tested through hundreds of iterations to withstand the rigors of daily use while providing reliable assistance.
- Continuous Software Updates: Enables the glasses to expand their capabilities and assist with a wider range of activities, such as reading, shopping, and hiking.

How it works:
The .lumen glasses use embedded computer vision, machine learning, and haptic feedback to understand the user's environment in real-time. Six cameras and various sensors map the surroundings, identifying obstacles, terrain types, and safe pathways. The AI processes this information to generate navigational commands, which are communicated to the user through intuitive haptic feedback.

Integrations:
The glasses are designed to be a standalone device and do not require integration with other devices or systems.

Use of AI:
The .lumen glasses rely heavily on AI technologies, including computer vision and machine learning, to process the user's environment and generate navigational commands.

AI foundation model:
The specific AI foundation model used in the .lumen glasses has not been disclosed.

How to access:
The .lumen glasses are currently available for registration for clinical investigation, with the product expected to be available to the general public in the second half of 2024.